All companies › TNGX

TNGX · Tango Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells5
Research cases0
Last filing2026-10-01

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-22 — Newcomb Jessica · sold 2,400 @ $25.17 2026-09-22 — Newcomb Jessica · sold 5,100 @ $23.97 2026-09-22 — Newcomb Jessica · sold 700 @ $22.80 2026-10-01 — Crystal Adam · sold 26,400 @ $24.45 2026-10-01 — Crystal Adam · sold 600 @ $25.32
2026-09-222026-10-01

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Newcomb Jessica Principal Accounting Officer
Crystal Adam President, R&D
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $TNGX is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-01', 'insider_name': 'Crystal Adam', 'insider_title': 'President, R&D', 'transaction_type': 'Open-market sell', 'shares': 26400.0, 'price': 24.4547, 'value': 645604.08, 'is_buy': False}, {'transaction_date': '2026-10-01', 'insider_name': 'Crystal Adam', 'insider_title': 'President, R&D', 'transaction_type': 'Open-market sell', 'shares': 600.0, 'price': 25.32, 'value': 15192.0, 'is_buy': False}, {'transaction_date': '2026-09-22', 'insider_name': 'Newcomb Jessica', 'insider_title': 'Principal Accounting Officer', 'transaction_type': 'Open-market sell', 'shares': 2400.0, 'price': 25.17, 'value': 60408.0, 'is_buy': False}, {'transaction_date': '2026-09-22', 'insider_name': 'Newcomb Jessica', 'insider_title': 'Principal Accounting Officer', 'transaction_type': 'Open-market sell', 'shares': 5100.0, 'price': 23.97, 'value': 122247.0, 'is_buy': False}, {'transaction_date': '2026-09-22', 'insider_name': 'Newcomb Jessica', 'insider_title': 'Principal Accounting Officer', 'transaction_type': 'Open-market sell', 'shares': 700.0, 'price': 22.8, 'value': 15960.0, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for TNGX today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.